Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Adverse Events
42%
Bone Metastasis
14%
Bone Turnover Markers
14%
Cancer Metastasis
100%
Cochrane Collaboration
14%
Confidence Interval
100%
Controlled Clinical Trial
14%
Denosumab
100%
Embase
14%
Event Risk
14%
Event Time
14%
Hazard Ratio
14%
Hypocalcemia
14%
Literature Search
14%
Low Incidence
14%
MEDLINE
14%
Meta-analysis
100%
No Significant Difference
14%
Osteonecrosis of the Jaw
14%
Overall Mortality
14%
Overall Survival
28%
Pain Level
14%
Patients with Cancer
100%
Quality of Life
14%
Risk Ratio
85%
Skeletal Metastases
100%
Skeletal-related Events
100%
Systematic Literature Review
14%
Web of Science
14%
Zoledronic Acid
57%
Medicine and Dentistry
Adverse Event
42%
Bone Metastasis
100%
Bone Turnover
14%
Controlled Clinical Trial
14%
Denosumab
100%
Hazard Ratio
14%
Hypocalcaemia
14%
Independent Reviewer
14%
Meta-Analysis
100%
Metastatic Carcinoma
100%
Osteonecrosis of the Jaw
14%
Overall Survival
28%
Quality of Life
14%
Systematic Review
100%
Zoledronic Acid
57%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
42%
Bone Metastasis
100%
Controlled Clinical Trial
14%
Denosumab
100%
Hypocalcaemia
14%
Jaw Osteonecrosis
14%
Overall Survival
28%
Zoledronic Acid
57%
Immunology and Microbiology
Bone Turnover
14%
Denosumab
100%
Jaw
14%
Overall Survival
28%
Web of Science
14%